Is Guanfacine already on the market in China?

The original version of Guanfacine (Guanfacine) has not yet been officially marketed in mainland China, but the research and development progress of domestic generic drugs has been significantly accelerated, and some companies have completed or are close to completing the clinical research stage. According to public information from the National Medical Products Administration (NMPA), many domestic pharmaceutical companies have submitted registration applications for guanfacine extended-release tablets, which are expected to be approved in the Chinese market in the next few years.

Guanfacine was originally developed byShire and marketed in the United States and Japan under the name Intuniv for the treatment of ADHD in children and adolescents aged 6 to 17 years. The Japanese version is sold by Takeda Pharmaceuticals (Takeda). It has been used clinically for a long time and has accumulated rich experience in the field of children's mental behavior. Unlike the European and American markets, China is more cautious in the introduction of children's psychotropic drugs, so the entry process of guanfacine is relatively lagging behind.

Currently, the main treatments for ADHD in mainland Chinaare methylphenidate and atomoxetine, both of which are conventional drugs on the market. As a non-stimulant drug, guanfacine has the characteristics of mild sedation, low risk of addiction, and can be used in combination with other drugs. It is considered to be an important supplementary solution in the future. With the increasing demand for non-stimulant drugs from parents and clinicians, guanfacine's market potential in China is generally optimistic.

According to overseas experience, the efficacy of guanfacine is stable in improving attention, reducing hyperactivity and impulsive behavior, and is well tolerated. At the regulatory level, China's drug regulatory agencies have gradually accelerated the review of children's neurological drugs, especially innovative and generic treatment options for ADHD. It is expected that with the parallel advancement of policies and R&D, domestic generic drugs will be the first to be launched on the market, while original drugs may re-enter the market in the future through imported drug registration channels.

In summary, guanfacine has not yet been officially sold in China, but it is in the late stages of research and development. The experience in using the Japanese and American versions provides an important reference for its clinical promotion in China.

Reference materials:https://go.drugbank.com/drugs/DB01018